Document:

EX-10.1

 Exhibit 10.1 

July 9, 2020 
 Gary Burnison 

c/o Korn Ferry 
 1900 Avenue of the Stars, Suite 2600 

Los Angeles, CA 90067 
  

	RE:	 Amended and Restated Employment Agreement dated as of March 30, 2018 between Korn Ferry (“Korn
Ferry”) and Gary Burnison (“Employment Agreement”) and the Letter Agreement dated as of April 14, 2020 

 Dear
Gary: 
 Reference is made to the Letter Agreement, dated April 14, 2020, between you and Korn Ferry, which amended the applicable terms and conditions
of your Employment Agreement (the “Employment Agreement Amendment”). This letter amends the Employment Agreement Amendment by deleting the reference to “August 31, 2020” and substituting in its stead “December 31,
2020”, having the effect of extending the temporary reduction of your annual rate of base salary described in the Employment Agreement Amendment through December 31, 2020. It is agreed that the extension of the temporary salary reduction
above shall not, alone, be a basis for Good Reason or any constructive termination claim and does not constitute Good Reason under your Employment Agreement. Except as expressly modified by this letter, the terms and conditions set forth in the
Employment Agreement and the Employment Agreement Amendment remain in full force and effect and are incorporated herein by reference. 
 Please indicate
your acceptance of this letter agreement amending your Employment Agreement and the Employment Agreement Amendment by signing and dating a copy of this letter agreement in the spaces provided below and returning such signed and dated copy to me. I
thank you for your continued commitment to Korn Ferry. 
  

							
		 		 		 	Sincerely,
		 		 		 	 /s/ Christina Gold

		 		 		 	Christina Gold

 ACCEPTED AND AGREED TO: 
  

							
	 /s/ Gary D. Burnison
	 		 		 	 July 9,
2020                                        

	Gary D. Burnison	 		 		 	 Date of SignatureEX-10.2

 Exhibit 10.2 

July 8, 2020 
 Robert Rozek 

c/o Korn Ferry 
 1900 Avenue of the Stars, Suite 2600 

Los Angeles, CA 90067 
  

	Re:	 Employment Agreement dated as of February 6, 2012 between Korn Ferry (“Korn Ferry”) and Robert
Rozek, as amended by that Amendment thereto dated as of December 28, 2015(“Employment Agreement”) and the Letter Agreement dated as of April 14, 2020 

Dear Bob: 
 Reference is made to the Letter Agreement, dated
April 14, 2020, between you and Korn Ferry, which amended the applicable terms and conditions of your Employment Agreement (the “Employment Agreement Amendment”). This letter amends the Employment Agreement Amendment by deleting the
reference to “August 31, 2020” and substituting in its stead “December 31, 2020”, having the effect of extending the temporary reduction of your annual rate of base salary described in the Employment Agreement Amendment through
December 31, 2020. It is agreed that the extension of the temporary salary reduction above shall not, alone, be a basis for Good Reason or any constructive termination claim and does not constitute Good Reason under your Employment Agreement.
Except as expressly modified by this letter, the terms and conditions set forth in the Employment Agreement and the Employment Agreement Amendment remain in full force and effect and are incorporated herein by reference. 

Please indicate your acceptance of this letter agreement amending your Employment Agreement and the Employment Agreement Amendment by signing and dating a
copy of this letter agreement in the spaces provided below and returning such signed and dated copy to me. I thank you for your continued commitment to Korn Ferry. 
  

							
		 		 		 	Sincerely,
				
		 		 		 	 /s/ Jonathan Kuai

		 		 		 	Jonathan Kuai

 ACCEPTED AND AGREED TO: 
  

							
	 /s/ Robert P. Rozek
	 		 		 	 July 8,
2020                                         
   

	Robert P. Rozek	 		 		 	 Date of SignatureEX-10.3

 Exhibit 10.3 

July 9, 2020 
 Byrne Mulrooney 

c/o Korn Ferry 
 1900 Avenue of the Stars, Suite 2600 

Los Angeles, CA 90067 
  

	Re:	 Employment Letter dated as of June 26, 2014 between Korn Ferry (“Korn Ferry”) and Byrne Mulrooney,
as amended by any changes made to certain terms described therein but not documented as formal amendments to the terms thereof (“Employment Letter”) and the Letter Agreement dated as of April 14, 2020 

Dear Byrne: 
 Reference is made to the Letter Agreement, dated
April 14, 2020, between you and Korn Ferry, which amended the applicable terms and conditions of your Employment Letter (the “Employment Letter Amendment”). This letter amends the Employment Letter Amendment by deleting the reference
to “August 31, 2020” and substituting in its stead “December 31, 2020”, having the effect of extending the temporary reduction of your annual rate of base salary described in the Employment Letter Amendment through
December 31, 2020. It is agreed that the extension of the temporary salary reduction above shall not, alone, be a basis for Good Reason or any constructive termination claim and does not constitute Good Reason under your Employment Letter.
Except as expressly modified by this letter, the terms and conditions set forth in the Employment Letter and the Employment Letter Amendment remain in full force and effect and are incorporated herein by reference. 

Please indicate your acceptance of this letter agreement amending your Employment Letter and the Employment Letter Amendment by signing and dating a copy of
this letter agreement in the spaces provided below and returning such signed and dated copy to me. I thank you for your continued commitment to Korn Ferry. 
  

							
		 		 		 	Sincerely,
				
		 		 		 	 /s/ Jonathan Kuai

		 		 		 	Jonathan Kuai

 ACCEPTED AND AGREED TO: 
  

							
	 /s/ Byrne Mulrooney
	 		 		 	 July 9,
2020                                        

	Byrne Mulrooney	 		 		 	 Date of SignatureEX-10.4

 Exhibit 10.4 

July 8, 2020 
 Mark Arian 

c/o Korn Ferry 
 1900 Avenue of the Stars, Suite 2600 

Los Angeles, CA 90067 
  

	Re:	 Employment Letter dated as of March 17, 2017 between Korn Ferry (“Korn Ferry”) and Mark Arian
(“Employment Letter”) and the Letter Agreement dated as of April 14, 2020 

 Dear Mark: 

Reference is made to the Letter Agreement, dated April 14, 2020, between you and Korn Ferry, which amended the applicable terms and conditions of your
Employment Letter (the “Employment Letter Amendment”). This letter amends the Employment Letter Amendment by deleting the reference to “August 31, 2020” and substituting in its stead “December 31, 2020”, having the
effect of extending the temporary reduction of your annual rate of base salary described in the Employment Letter Amendment through December 31, 2020. It is agreed that the extension of the temporary salary reduction above shall not, alone, be
a basis for Good Reason or any constructive termination claim and does not constitute Good Reason under your Employment Letter. Except as expressly modified by this letter, the terms and conditions set forth in the Employment Letter and the
Employment Letter Amendment remain in full force and effect and are incorporated herein by reference. 
 Please indicate your acceptance of this letter
agreement amending your Employment Letter and the Employment Letter Amendment by signing and dating a copy of this letter agreement in the spaces provided below and returning such signed and dated copy to me. I thank you for your continued
commitment to Korn Ferry. 
  

							
		 		 		 	Sincerely,
				
		 		 		 	 /s/ Jonathan Kuai

		 		 		 	Jonathan Kuai

 ACCEPTED AND AGREED TO: 
  

							
	 /s/ Mark Arian
	 		 		 	 July 8,
2020                                        

	Mark Arian	 		 		 	 Date of SignatureEX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 STOCK
PURCHASE AGREEMENT 
  

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 Section 1.
	 	 Purchase and Sale of Common Stock
	  	 	1	 
	 1.1
	 	Sale and Issuance of the Shares	  	 	1	 
	 1.2
	 	Closing; Delivery	  	 	1	 
	 1.3
	 	Defined Terms Used in this Agreement	  	 	2	 
	 1.4
	 	Construction	  	 	3	 
			
	 Section 2.
	 	Representations and Warranties of the Company	  	 	4	 
	 2.1
	 	Organization, Good Standing and Qualification	  	 	4	 
	 2.2
	 	Authorization	  	 	4	 
	 2.3
	 	Capitalization	  	 	4	 
	 2.4
	 	Valid Issuance	  	 	5	 
	 2.5
	 	Consents	  	 	5	 
	 2.6
	 	Use of Proceeds	  	 	5	 
	 2.7
	 	No Material Adverse Change	  	 	5	 
	 2.8
	 	SEC Filings	  	 	6	 
	 2.9
	 	No Conflict, Breach, Violation or Default	  	 	6	 
	 2.10
	 	Tax Matters	  	 	7	 
	 2.11
	 	Title to Properties	  	 	7	 
	 2.12
	 	Certificates, Authorities and Permits	  	 	7	 
	 2.13
	 	Labor Matters	  	 	8	 
	 2.14
	 	Intellectual Property	  	 	8	 
	 2.15
	 	Tests and Preclinical and Clinical Trials	  	 	8	 
	 2.16
	 	Environmental Matters	  	 	8	 
	 2.17
	 	Legal Proceedings	  	 	9	 
	 2.18
	 	Financial Statements	  	 	9	 
	 2.19
	 	Insurance	  	 	9	 
	 2.20
	 	Nasdaq Listing	  	 	9	 
	 2.21
	 	Brokers and Finders	  	 	9	 
	 2.22
	 	No Directed Selling Efforts or General Solicitation	  	 	10	 
	 2.23
	 	No Integrated Offering	  	 	10	 
	 2.24
	 	Private Placement	  	 	10	 
	 2.25
	 	Foreign Corrupt Practices	  	 	10	 
	 2.26
	 	Transactions with Affiliates	  	 	10	 
	 2.27
	 	Internal Controls	  	 	10	 
	 2.28
	 	Manipulation of Price	  	 	11	 
	 2.29
	 	No Bad Actors	  	 	11	 
	 2.30
	 	Investment Company	  	 	11	 
			
	 Section 3.
	 	Representations and Warranties of the Investor	  	 	11	 
	 3.1
	 	Organization	  	 	11	 
	 3.2
	 	Authorization	  	 	11	 
	 3.3
	 	Purchase Entirely for Own Account	  	 	11	 
	 3.4
	 	Investment Experience	  	 	12	 

							
	 3.5
	 	Disclosure of Information	  	 	12	 
	 3.6
	 	Restricted Securities	  	 	12	 
	 3.7
	 	Legends	  	 	12	 
	 3.8
	 	Accredited Investor	  	 	12	 
	 3.9
	 	No General Solicitation	  	 	13	 
	 3.10
	 	Brokers and Finders	  	 	13	 
	 3.11
	 	Short Sales and Confidentiality Prior to the Date Hereof	  	 	13	 
	 3.12
	 	No Government Recommendation or Approval	  	 	13	 
	 3.13
	 	No Conflicts	  	 	13	 
	 3.14
	 	Residency	  	 	14	 
	 3.15
	 	Financial Capability	  	 	14	 
			
	 Section 4.
	 	Covenants	  	 	14	 
	 4.1
	 	Legend Removal	  	 	14	 
	 4.2
	 	Short Sales and Confidentiality After the Date Hereof	  	 	15	 
			
	 Section 5.
	 	Conditions to Closing	  	 	15	 
	 5.1
	 	Conditions to the Investor’s Obligations	  	 	15	 
	 5.2
	 	Conditions to Obligations of the Company	  	 	16	 
	 5.3
	 	Termination of Obligations to Effect Closing; Effects	  	 	16	 
			
	 Section 6.
	 	Miscellaneous	  	 	17	 
	 6.1
	 	Successors and Assigns	  	 	17	 
	 6.2
	 	Governing Law	  	 	17	 
	 6.3
	 	Counterparts	  	 	17	 
	 6.4
	 	Titles and Subtitles	  	 	18	 
	 6.5
	 	Notices	  	 	18	 
	 6.6
	 	No Finder’s Fees	  	 	18	 
	 6.7
	 	Expenses	  	 	18	 
	 6.8
	 	Waiver	  	 	18	 
	 6.9
	 	Amendments	  	 	18	 
	 6.10
	 	Severability	  	 	18	 
	 6.11
	 	Entire Agreement	  	 	19	 
	 6.12
	 	Specific Enforcement	  	 	19	 
	 6.13
	 	Exclusive Jurisdiction; Venue	  	 	19	 
	 6.14
	 	Publicity	  	 	20	 
	 6.15
	 	Survival	  	 	20	 
	 6.16
	 	Waiver of Jury Trial	  	 	20	 

  

  
 ii 

 STOCK PURCHASE AGREEMENT 

THIS STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of July 9, 2020, by and between
Vaccinex, Inc., a Delaware corporation (the “Company”), and Friedberg Global-Macro Hedge Fund Ltd. (the “Investor”). 

RECITALS 

WHEREAS, the Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from
securities registration afforded by the provisions of Section 4(a)(2) of the 1933 Act (as defined below) and Rule 506 of Regulation D (“Regulation D”) as promulgated by the SEC (as defined below) under the 1933 Act; 

WHEREAS, the Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor,
upon the terms and subject to the conditions stated in this Agreement, an aggregate of 1,126,760 shares (the “Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”); and 

WHEREAS, contemporaneously with the sale of the Shares, the parties hereto will execute and deliver a Registration
Rights Agreement, in the form attached hereto as Exhibit A (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights in respect of the Shares under the 1933 Act;

 The parties hereby agree as follows: 
  

	 	Section 1.	 Purchase and Sale of Common Stock. 

 

	 	1.1	 Sale and Issuance of the Shares. On the Closing Date (as defined below), upon the terms and
subject to the conditions set forth herein, the Company will sell and issue, and the Investor will purchase, for a price of $3.55 per Share, the Shares. 

  

	 	1.2	 Closing; Delivery. 

(a) Subject to the satisfaction or waiver of the conditions set forth in Section 5, the completion
of the purchase and sale of the Shares (the “Closing”) shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) determined by the Company and of which the Investor will be
notified at least two days in advance by the Company but (i) in no event earlier than the second Business Day after the date hereof and (ii) in no event later than the fifth Business Day after the date hereof, or as otherwise agreed to by
the Company and the Investor. 
 (b) On the Closing Date, the Investor shall deliver or cause to be delivered to the
Company, via wire transfer of immediately available funds pursuant to the wire instructions delivered to the Investor by the Company on or prior to the Closing Date, an amount equal to $4,000,000. 

 (c) At the Closing, the Company shall deliver irrevocable instructions to
the transfer agent and registrar for the Common Stock (the “Transfer Agent”) to issue to the Investor 1,126,760 Shares, registered in the name of the Investor (or its nominee in accordance with its delivery instructions). The Shares
shall be delivered within one Trading Day of the Closing via a book-entry record through the Transfer Agent. 
  

	 	1.3	 Defined Terms Used in this Agreement. In addition to the terms defined elsewhere in this Agreement,
the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below. 

(a) “1933 Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and
regulations promulgated thereunder. 
 (b) “1934 Act” means the Securities Exchange Act of 1934, as
amended, or any successor statute, and the rules and regulations promulgated thereunder. 
 (c) “Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with such Person. 

(d) “Business Day” means any day except Saturday, Sunday and any legal holiday or a day on which banking
institutions in New York, New York generally are authorized or required by law or other governmental actions to close. 

(e) “Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule
506 promulgated under the 1933 Act, any Person listed in the first paragraph of Rule 506(d)(1). 
 (f)
“Company’s Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company. 

(g) “Control” (including the terms “controlling,” “controlled by” or “under common
control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

(h) “Material Adverse Effect” means any fact, circumstance, change, event, occurrence or effect that,
individually, or in the aggregate with any such other facts, circumstances, changes, events, occurrences or effects, would have, or would reasonably be expected to have, a material adverse effect on the financial condition, business, properties,
assets, liabilities, or results of operations of the Company and its Subsidiary, taken as a whole. 
 (i) “Material
Contract” means any contract, instrument or other agreement to which the Company is a party or by which it is bound that has been filed or was required to have been filed as an exhibit to the SEC Filings (as defined below) pursuant to
Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 
 (j)
“Nasdaq” means the Nasdaq Capital Market. 

  
 2 

 (k) “Person” means any individual, firm, corporation,
limited liability company, partnership, company or other entity, and shall include any successor (by merger or otherwise) of such entity. 

(l) “Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and
quoted for trading, which, as of the date of this Agreement and the Closing Date, shall be Nasdaq. 
 (m)
“SEC” means the U.S. Securities and Exchange Commission. 
 (n) “Short Sales” means all
“short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 

(o) “Subsidiary” means, with respect to any Person, any corporation, association or other business entity of
which more than 50% of the voting power of the outstanding Voting Stock or of the membership interests is owned, directly or indirectly, by such Person and/or one or more other Subsidiaries of such Person. 

(p) “Trading Day” means (i) a day on which the Common Stock is listed or quoted and traded on its
Principal Trading Market (other than the OTC Bulletin Board, OTCQX or OTCQB), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board, OTCQX or OTCQB), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board or OTC Markets Group Inc., as applicable, or (iii) if the Common Stock is not quoted on any Trading Market,
a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by OTC Markets Group Inc. (or any similar
organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) or (iii) hereof, then Trading Day shall mean a Business Day.

 (q) “Trading Market” means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq
Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, the OTC Bulletin Board, OTCQX or OTCQB on which the Common Stock is listed or quoted for trading on the date in question. 

(r) “Transaction Documents” means this Agreement and the Registration Rights Agreement. 

(s) “Voting Stock” means, with respect to any Person, capital stock of any class or kind ordinarily having
the power to vote for the election of directors, managers or other voting members of the governing body of such Person. 
  

	 	1.4	 Construction. Whenever required by the context, any pronoun used in this Agreement shall include the
corresponding masculine, feminine or neuter forms, and the singular forms of nouns, pronouns, and verbs shall include the plural and vice versa. Reference to any agreement, document, or instrument means such agreement, document, or instrument as
amended or otherwise modified from time to time in accordance with the 

  
 3 

	 	 
terms thereof and, if applicable, hereof. A reference to either party hereto includes such party’s permitted assignees and/or the respective successors in title to substantially the whole of
such party’s undertaking. All references to “Sections” and “Exhibits” contained in this Agreement are, unless specifically indicated otherwise, references to sections or exhibits of or to this Agreement. The recitals and
exhibits to this Agreement form part of the operative provisions of this Agreement and references to this Agreement shall, unless the context otherwise requires, include references to the recitals and exhibits to this Agreement. As used in this
Agreement, the following terms shall have the meanings indicated: (a) “day” means a calendar day; (b) “United States” means the United States of America; (c) “dollar” or “$” means lawful currency of the United
States; (d) “including” or “include” means “including without limitation”; and (e) references in this Agreement to specific laws includes the succeeding law, section, or provision corresponding thereto and the
rules and regulations promulgated thereunder. 

  

	 	Section 2.	 Representations and Warranties of the Company. The Company hereby represents and warrants to the
Investor that, except as described in the Company’s SEC Filings (as defined below), which qualify these representations and warranties in their entirety: 

 

	 	2.1	 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties. The Company is duly qualified to
do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had
and would not reasonably be expected to have a Material Adverse Effect. The Company’s Subsidiary is set forth on Exhibit 21.1 to its most recent Annual Report on Form 10-K, and the Company owns 80% of the
outstanding equity of such Subsidiary and is its sole general partner. The Company’s Subsidiary is duly organized and validly existing and in good standing under the laws of its jurisdiction of incorporation and has all requisite power and
authority to carry on its business as now conducted. The Company’s Subsidiary is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or
leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect. 

 

	 	2.2	 Authorization. The Company has the requisite corporate power and authority and has taken all
requisite corporate action necessary for, and no further action on the part of the Company, its officers, directors and 

  
 4 

	 	 
stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company
hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Shares. This Agreement constitutes, and the Registration Rights Agreement when executed will constitute, the legal, valid and
binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting
creditors’ rights generally and to general equitable principles. 

  

	 	2.3	 Capitalization. The Company is authorized under its Certificate of Incorporation to issue 100,000,000
shares of Common Stock. As of the date hereof, a total of 17,123,482 shares of Common Stock are issued and outstanding, and there are a total of 3,325,052 shares of Common Stock underlying stock options and other securities exercisable for,
convertible into or exchangeable for shares of Common Stock. All the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid and nonassessable. No Person is entitled to
preemptive or similar statutory or contractual rights with respect to the issuance by the Company of any securities of the Company, including, without limitation, the Shares. Except for stock options approved pursuant to Company stock-based
compensation plans described in the SEC Filings and securities exercisable for, convertible into or exchangeable for shares of capital stock of the Company disclosed in the SEC Filings, there are no outstanding warrants, options, convertible
securities or other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this Agreement. There are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by
them. Except as disclosed in the SEC Filings, no Person has the right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the
Company for its own account or for the account of any other Person. The issuance and sale of the Shares hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investor) and
will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. The Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect
giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 

  
 5 

	 	2.4	 Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for
pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by the Investor), except for restrictions on transfer set forth in the
Transaction Documents or imposed by applicable securities laws. 

  

	 	2.5	 Consents. The execution, delivery and performance by the Company of the Transaction Documents and the
offer, issuance and sale of the Shares require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than (a) filings that have been made pursuant to applicable state securities
laws, (b) post-sale filings pursuant to applicable state and federal securities laws, (c) filings pursuant to the rules and regulations of Nasdaq and (d) filing of the registration statement required to be filed by the Registration
Rights Agreement, each of which the Company has filed or undertakes to file within the applicable time. 

  

	 	2.6	 Use of Proceeds. The net proceeds of the sale of the Shares hereunder shall be used by the Company to
fund the ongoing development of pepinemab and for working capital and general corporate purposes. 

  

	 	2.7	 No Material Adverse Change. Since December 31, 2019, except as identified and described in the
SEC Filings filed at least one Trading Day prior to the date hereof, there has not been: 

 (a) any change
in the consolidated assets, liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the SEC Filings, except for changes in the ordinary course of business which have not had
and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 
 (b) any
declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company;

 (c) any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the
Company; 
 (d) any waiver, not in the ordinary course of business, by the Company of a material right or of a material debt
owed to it; 
 (e) any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the
Company, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted); 

  
 6 

 (f) any change or amendment to the Company’s Certificate of
Incorporation or Bylaws, or material change to any Material Contract or arrangement by which the Company is bound or to which any of its assets or properties is subject; 

(g) any material labor difficulties or, to the Company’s Knowledge, labor union organizing activities with respect to
employees of the Company; 
 (h) any material transaction entered into by the Company other than in the ordinary course of
business or as otherwise disclosed in writing to the Investor; 
 (i) the loss of the services of any key employee, or
material change in the composition or duties of the senior management of the Company; or 
 (j) any other event or condition
of any character that has had or would reasonably be expected to have a Material Adverse Effect. 
  

	 	2.8	 SEC Filings. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year period preceding the date hereof (or such shorter period as the Company was required by law or
regulation to file such material) (collectively, the “SEC Filings”). At the time of filing thereof, the SEC Filings complied in all material respects with the requirements of the 1933 Act or the 1934 Act, as applicable, and the
rules and regulations of the SEC thereunder. 

  

	 	2.9	 No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction
Documents by the Company and the issuance and sale of the Shares in accordance with the provisions hereof will not, except (solely in the case of clauses (i)(b) and (ii)) for such violations, conflicts or defaults as would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect, (i) conflict with or result in a breach or violation of (a) any of the terms and provisions of, or constitute a default under, the Company’s Certificate of
Incorporation or the Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investor through the Electronic Data Gathering, Analysis, and Retrieval system (the “EDGAR
system”)), or (b) assuming the accuracy of the representations and warranties in Section 3, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or
foreign, having jurisdiction over the Company or its Subsidiary, or any of their assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or its Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation

  
 7 

	 	 
(with or without notice, lapse of time or both) of, any Material Contract. This Section does not relate to matters with respect to tax status, which are the subject of
Section 2.10, employee relations and labor matters, which are the subject of Section 2.13, or Environmental Laws (as defined below), which are the subject of Section 2.16.

  

	 	2.10	 Tax Matters. The Company and its Subsidiary have timely prepared and filed all material tax returns
required to have been filed by them with all appropriate governmental agencies and timely paid all material taxes shown thereon or otherwise owed by them. There are no material unpaid assessments against the Company nor, to the Company’s
Knowledge, any audits by any federal, state or local taxing authority. All material taxes that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or
third party when due. There are no tax liens pending or, to the Company’s Knowledge, threatened against the Company or any of its assets or property. With the exception of agreements or other arrangements that are not primarily
related to taxes entered into in the ordinary course of business, there are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity (other than a subsidiary of the Company).

  

	 	2.11	 Title to Properties. The Company and its Subsidiary have good and marketable title to all real
properties and all other properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the
Company and its Subsidiary hold any leased real or personal property under valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

  

	 	2.12	 Certificates, Authorities and Permits. The Company possesses adequate certificates, authorities or
permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Effect. The Company has not received any written notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that would reasonably be expected to have a Material Adverse Effect, individually
or in the aggregate, on the Company. 

  

	 	2.13	 Labor Matters. The Company is not party to or bound by any collective bargaining agreements or other
agreements with labor organizations. To the Company’s Knowledge, the Company has not violated in any material respect any laws, regulations, orders or contract terms affecting 

  
 8 

	 	 
the collective bargaining rights of employees or labor organizations, or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees’
health, safety, welfare, wages and hours. No material labor dispute with the employees of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company’s Knowledge,
is threatened or imminent. 

  

	 	2.14	 Intellectual Property. To the Company’s Knowledge, the Company and its Subsidiary own, possess,
license or have other rights to use, all patents, copyrights, trademarks, service marks, trade names, service names, trade secrets and other intellectual property described in the SEC Filings necessary for the conduct of the Company’s business
as currently conducted and that the failure to so have would have or reasonably be expected to result in a Material Adverse Effect (collectively, the “Intellectual Property”). There is no pending or, to the Company’s
Knowledge, threatened action, suit, proceeding or claim by any Person that the Company’s business or the business of its Subsidiary as now conducted infringes or violates any patent, trademark, copyright, trade secret or other intellectual
property rights of another. To the Company’s Knowledge, there is no existing infringement by another Person of any of the Intellectual Property owned or exclusively licensed by the Company or its Subsidiary that would have or would
reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiary have taken reasonable security measures to protect the secrecy, confidentiality and value of the non-public portions of
the Intellectual Property owned or exclusively licensed by the Company or its Subsidiary, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

 

	 	2.15	 Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials
conducted by the Company or conducted on behalf of the Company that are described in the SEC Filings were and, if still pending, are being conducted in all material respects in accordance with the relevant experimental protocols, procedures and
controls and all applicable laws; the descriptions of the results of such studies, tests and trials contained in the SEC Filings are accurate and complete and fairly present the data derived from such studies, tests and trials in all material
respects as of the respective dates of such SEC Filings; the Company is not aware of any studies, tests or trials, the results of which the Company believes are materially inconsistent with the study, test or trial results described or referred to
in the SEC Filings when viewed in the context in which such results are described and the clinical state of development; and the Company has not received any notices or written correspondence from the U.S. Food and Drug Administration or any other
federal, state, local or foreign governmental or regulatory authority requiring the 

  
 9 

	 	 
termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company. 

 

	 	2.16	 Environmental Matters. The Company is not in violation of any material statute, rule, regulation,
decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to
hazardous or toxic substances (collectively, “Environmental Laws”), has not released any hazardous substances regulated by Environmental Law onto any real property that it owns or operates, and has not received any written notice or
claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect, and to the Company’s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim. 

 

	 	2.17	 Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, suits or
proceedings pending or, to the Company’s Knowledge, threatened in writing, to which the Company or its Subsidiary are or may reasonably be expected to become a party or to which any property of the Company or its Subsidiary are or may
reasonably be expected to become the subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. 

  

	 	2.18	 Financial Statements. The financial statements included in the SEC Filings comply in all material
respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and present fairly, in all material respects,
the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements to normal
year-end audit adjustments, and such consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis during the
periods involved (“GAAP”) (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly financial
statements, except as permitted by Form 10-Q under the 1934 Act). 

  

	 	2.19	 Insurance. The Company maintains in full force and effect insurance coverage that is customary for
comparably situated companies for the business being conducted and properties owned or leased by the 

  
 10 

	 	 
Company, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims and risks against which it is customary for comparably situated companies to
insure. 

  

	 	2.20	 Nasdaq Listing. The Company is in compliance with applicable Nasdaq continued listing requirements.
There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge
is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. 

  

	 	2.21	 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the
Transaction Documents, any valid right, interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.
No Investor shall have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 2.21 that may be due in
connection with the transactions contemplated by the Transaction Documents. 

  

	 	2.22	 No Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its
behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D promulgated under the 1933 Act) in connection with the offer or sale of any of the Shares. 

 

	 	2.23	 No Integrated Offering. Neither the Company nor any Person acting on its behalf has, directly or
indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) and Regulation D for the exemption from
registration for the transactions contemplated hereby. 

  

	 	2.24	 Private Placement. Assuming the accuracy of the representations and warranties of the Investor set
forth in Section 3, the offer and sale of the Shares to the Investor as contemplated hereby is exempt from the registration requirements of the 1933 Act. The issuance and sale of the Shares does not contravene the rules and
regulations of Nasdaq. 

  

	 	2.25	 Foreign Corrupt Practices. Neither the Company, its Subsidiary, nor to the Company’s Knowledge,
any director, officer, agent, employee or other Person acting on behalf of the Company or its Subsidiary has, in the course of its actions for, or on behalf of, the Company or its Subsidiary: (i) used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to political 

  
 11 

	 	 
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of in any
material respect any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official
or employee. 

  

	 	2.26	 Transactions with Affiliates. Except as disclosed in the SEC Filings, none of the executive officers
or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company or its Subsidiary is presently a party to any transaction with the Company or its Subsidiary (other than as holders of stock options and/or
restricted stock, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or
otherwise requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or
partner. 

  

	 	2.27	 Internal Controls. The Company has established and maintains disclosure controls and procedures (as
defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are designed to ensure that material information relating to the Company, including its Subsidiary, is made
known to the Company’s principal executive officer and its principal financial officer by others within those entities. Since the end of the Company’s most recent audited fiscal year, there have been no material weaknesses in the
Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or would reasonably be expected to materially affect,
the Company’s internal control over financial reporting. The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or would
reasonably be expected to materially affect, the Company’s internal control over financial reporting. 

  

	 	2.28	 Manipulation of Price. The Company has not taken, nor will it take, directly or indirectly any action
designed to stabilize or manipulate the price of the Common Stock or any security of the Company to facilitate the sale or resale of any of the Shares. 

  

	 	2.29	 No Bad Actors. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of
the 1933 Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s Knowledge, any 

  
 12 

	 	 
Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3) is applicable. 

 

	 	2.30	 Investment Company. The Company is not required to be registered as, and is not an Affiliate of, and
immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

 

	 	Section 3.	 Representations and Warranties of the Investor. The Investor hereby represents and
warrants to the Company that: 

  

	 	3.1	 Organization. The Investor is a duly organized and validly existing legal entity and has all
requisite corporate, partnership, limited liability company or similar power and authority, as applicable, to enter into and consummate the transactions contemplated by the Transaction Documents, to carry out its obligations hereunder and
thereunder, and to invest in the Shares pursuant to this Agreement, and is in good standing under the laws of the jurisdiction of its organization. 

  

	 	3.2	 Authorization. The execution, delivery and performance by the Investor of the Transaction Documents
have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of the Investor, and each has been duly executed and when delivered will constitute the valid and legally
binding obligation of the Investor, enforceable against the Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to
or affecting creditors’ rights generally, and general principles of equity. 

  

	 	3.3	 Purchase Entirely for Own Account. The Shares to be received by the Investor hereunder will be
acquired for the Investor’s own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and the Investor has no present intention of
selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to the Investor’s right at all times to sell or otherwise dispose of all or any part of such Shares in
compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by the Investor to hold the Shares for any period of time. The Investor is not a broker-dealer registered with the
SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 

  

	 	3.4	 Investment Experience. The Investor acknowledges that it can bear the economic risk and complete loss
of its investment in the Shares and has such knowledge and experience in financial or business matters that it is 

  
 13 

	 	 
capable of evaluating the merits and risks of the investment contemplated hereby. 

  

	 	3.5	 Disclosure of Information. The Investor has had an opportunity to receive, review and understand all
information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares, and has conducted and completed its own
independent due diligence. The Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on the information the Investor has deemed appropriate, it has independently made its own analysis and decision to enter
into the Transaction Documents. The Investor is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance of the Transaction
Documents, the Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit and tax matters. Neither
such inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit or otherwise affect the Investor’s right to rely on the Company’s representations and warranties contained in this Agreement.

  

	 	3.6	 Restricted Securities. The Investor understands that the Shares are characterized as “restricted
securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without
registration under the 1933 Act only in certain limited circumstances. 

  

	 	3.7	 Legends. It is understood that, except as provided below, certificates evidencing the Shares (or
uncertificated interests in the Shares) may bear the following or any similar legend: 

 (a) “THE
SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

(b) If required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by
such state authority. 

  
 14 

	 	3.8	 Accredited Investor. The Investor is (a) an “accredited investor” within the meaning
of Rule 501(a) of Regulation D. The Investor has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit B (the “Investor Questionnaire”), which the Investor represents and
warrants is true, correct and complete. The Investor is a sophisticated institutional investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits of its purchase of the
Shares. 

  

	 	3.9	 No General Solicitation. The Investor did not learn of the investment in the Shares as a result of
any general or public solicitation or general advertising, or publicly disseminated advertisements or sales literature, including (a) any advertisement, article, notice or other communication published in any newspaper, magazine, website, or
similar media, or broadcast over television or radio, or (b) any seminar or meeting to which the Investor was invited by any of the foregoing means of communications. 

 

	 	3.10	 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the
Transaction Documents, any valid right, interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Investor.

  

	 	3.11	 Short Sales and Confidentiality Prior to the Date Hereof. Other than consummating the transactions
contemplated hereunder, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the
Company during the period commencing as of the time that the Investor was first contacted by the Company or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof. The Investor, its
Affiliates and authorized representatives and advisors who are aware of the transactions contemplated by the Transaction Documents have maintained the confidentiality of all disclosures made to the Investor in connection with the transactions
contemplated by the Transaction Documents (including the existence and terms of such transactions). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any
actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. 

 

	 	3.12	 No Government Recommendation or Approval. The Investor understands that no United States federal or
state agency, or similar agency of any other country, has reviewed, approved, passed upon, or 

  
 15 

	 	 
made any recommendation or endorsement of the Company or the purchase of the Shares. 

  

	 	3.13	 No Conflicts. The execution, delivery and performance by the Investor of the Transaction Documents
and the consummation by the Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Investor or (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Investor is a party, or
(iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Investor, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Investor to perform its obligations hereunder. 

 

	 	3.14	 Residency. The Investor’s office in which its investment decision with respect to the Shares was
made is located in Toronto, Ontario, Canada. 

  

	 	3.15	 Financial Capability. The Investor has immediately available funds necessary to consummate the
Closing on the terms and conditions contemplated by this Agreement. 

  

	 	Section 4.	 Covenants. 

 

	 	4.1	 Legend Removal.  

(a) In connection with any sale, assignment, transfer or other disposition of the Shares by the Investor pursuant to
Rule 144 or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall
cause the Transfer Agent to remove any restrictive legends related to the book-entry account holding such Shares and make a new, unlegended book entry for such Shares sold or disposed of without restrictive legends within two Trading Days of any
such request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection therewith. 

(b) Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other
documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) have been sold or transferred pursuant to an effective registration statement, (ii) have
been sold pursuant to Rule 144, or (iii) are eligible for resale under Rule 144(b)(1) or any successor provision, the Company shall, in accordance with the provisions of this Section 4.1(b) and within
three Trading Days of any request therefor from the Investor accompanied by such customary and reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent 

  
 16 

 
irrevocable instructions that the Transfer Agent shall make a new, unlegended book entry for such Shares, (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the
effect that the removal of such legends in such circumstances may be effected under the 1933 Act if required by the Transfer Agent to effect the removal of the legend, and (C) deliver or cause to be delivered to the Investor a new, unlegended
book-entry notation or other evidence that the legend has been removed. 
 (c) The Investor agrees with the Company
(i) that the Investor will sell any Shares pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption therefrom, (ii) that if Shares are sold pursuant to a
registration statement, they will be sold in compliance with the plan of distribution set forth therein and (iii) that if, after the effective date of the registration statement covering the resale of the Shares, such registration statement is
not then effective and the Company has provided notice to the Investor to that effect, the Investor will sell Shares only in compliance with an exemption from the registration requirements of the 1933 Act. 

 

	 	4.2	 Short Sales and Confidentiality After the Date Hereof. The Investor covenants that neither it nor any
Affiliates acting on its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until the earlier of such time as (i) the transactions contemplated by this Agreement are first
publicly announced or (ii) this Agreement is terminated in full. The Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, the Investor will maintain (and will cause
its Affiliates, authorized representatives and advisors who are aware of the transactions contemplated by the Transaction Documents) to maintain the confidentiality of all disclosures made to it in connection with the transactions contemplated by
the Transaction Documents (including the existence and terms of such transactions). The Investor understands and acknowledges that the SEC currently takes the position that coverage of Short Sales of shares of the Common Stock “against the
box” prior to effectiveness of a resale registration statement with securities included in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in Item 239.10 of the Securities Act Rules Compliance
and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance, and covenants that neither it nor any Affiliates acting on its behalf or pursuant to any understanding with it will execute any such Short
Sales. 

  

	 	Section 5.	 Conditions to Closing. 

 

	 	5.1	 Conditions to the Investor’s Obligations. The obligation of the Investor to
purchase Shares at the Closing is subject to the fulfillment to the Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by the Investor: 

  
 17 

 (a) The representations and warranties made by the Company in
Section 2 hereof shall be true and correct as of the date hereof and as of the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier
date, in which case such representation or warranty shall be true and correct as of such earlier date. 
 (b) The Company
shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 

(c) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the
consummation of the purchase and sale of the Shares and the consummation of the other transactions contemplated by this Agreement, all of which shall be in full force and effect. 

(d) The Company shall have executed and delivered the Registration Rights Agreement. 

(e) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any
bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions
contemplated by the Transaction Documents. 
 (f) The Company shall have delivered a certificate, executed on behalf of the
Company by an officer of the Company, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a) through (c). (e), (h) and (i) of this Section 5.1. 

(g) The Company shall have delivered a certificate, executed on behalf of the Company by an officer of the Company, dated as
of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by the Transaction Documents and the issuance of the Shares, certifying the current versions of the Certificate
of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company. 

(h) There shall have been no Material Adverse Effect with respect to the Company since the date hereof. 

(i) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock. 
  

	 	5.2	 Conditions to Obligations of the Company. The Company’s obligation to sell and issue Shares at
the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

  
 18 

 (a) The representations and warranties made by the Investor in
Section 3 hereof shall be true and correct as of the date hereof, and shall be true and correct as of the Closing Date with the same force and effect as if they had been made on and as of such date. 

(b) The Investor shall have performed in all material respects all obligations and covenants herein required to be performed
by them on or prior to the Closing Date. 
 (c) The Investor shall have executed and delivered the Registration Rights
Agreement and an Investor Questionnaire. 
 (d) The Investor shall have paid in full its purchase price to the Company. 

 

	 	5.3	 Termination of Obligations to Effect Closing; Effects. 

(a) The obligations of the Company, on the one hand, and the Investor, on the other hand, to effect the Closing shall
terminate as follows: 
 (i) upon the mutual written consent of the Company and the Investor; 

(ii) by the Company if any of the conditions set forth in Section 5.2 shall have become incapable of
fulfillment, and shall not have been waived by the Company; 
 (iii) by the Investor if any of the conditions set forth in
Section 5.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 

(iv) by either the Company or the Investor if the Closing has not occurred on or prior to July 30, 2020; 

provided, however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect
the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate
its obligation to effect the Closing. 
 (b) Nothing in this Section 5.3 shall be deemed to
release either party from any liability for any breach by such party of the terms and provisions of the Transaction Documents or to impair the right of either party to compel specific performance by the other party of its obligations under the
Transaction Documents. 
  

	 	Section 6.	 Miscellaneous. 

 

	 	6.1	 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and
be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, 

  
 19 

	 	 
is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement. 

  

	 	6.2	 Governing Law. This Agreement and all claims or causes of action (whether in tort, contract or
otherwise) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or
warranty made in or in connection with this Agreement) shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. 

  

	 	6.3	 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail or other transmission method and any counterpart so delivered shall be deemed to have been duly
and validly delivered and be valid and effective for all purposes. 

  

	 	6.4	 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only
and are not to be considered in construing or interpreting this Agreement. 

  

	 	6.5	 Notices. All notices and other communications given or made pursuant to this Agreement shall be in
writing and shall be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient,
and if not sent during normal business hours, then on the recipient’s next Business Day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one Business Day after
deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address or e-mail address as set forth on the signature page, or to such address, e-mail address or facsimile number as subsequently modified by written notice given in accordance with
this Section 6.5. 

  

	 	6.6	 No Finder’s Fees. Each party represents that it neither is nor will be obligated
for any finder’s fee or commission in connection with this transaction. The Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the

  
 20 

	 	 
nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Investor
or any of the Investor’s officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless the Investor from any liability for any commission or compensation in the nature of a finder’s or
broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.

  

	 	6.7	 Expenses. Each party shall pay its own expenses (including fees and expenses of financial advisors,
attorneys and other advisors) incurred in connection with the preparation, negotiation, due diligence, execution, delivery, and performance of the Transaction Agreements and the consummation of the transactions contemplated hereby and thereby.

  

	 	6.8	 Waiver. Waiver by the Company or the Investor of a breach hereunder by the Investor or the Company,
respectively, shall not be construed as a waiver of any subsequent breach of the same or any other provision. No delay or omission by a party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later
exercise of any such right, power or privilege by such party. No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the party
granting the waiver. All remedies, either under this Agreement or by law or otherwise afforded to either party, shall be cumulative and not alternative. 

  

	 	6.9	 Amendments. Any term of this Agreement may be amended or terminated only with the written consent of
the Company and the Investor. 

  

	 	6.10	 Severability. If one or more of the terms or provisions of this Agreement is held by a court of
competent jurisdiction to be void, invalid, or unenforceable in any situation in any jurisdiction, such holding shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the
void, invalid, or unenforceable term or provision in any other situation or in any other jurisdiction, and the term or provision shall be considered severed from this Agreement solely for such situation and solely in such jurisdiction, unless the
void, invalid, or unenforceable term or provision is of such essential importance to this Agreement that it is to be reasonably assumed that the parties hereto would not have entered into this Agreement without the void, invalid, or unenforceable
term or provision. If the final judgment of such court declares that any term or provision hereof is void, invalid, or unenforceable, the parties hereto agree to: (a) reduce the scope, duration, area, or applicability of the term or provision

  
 21 

	 	 
or to delete specific words or phrases to the minimum extent necessary to cause such term or provision as so reduced or amended to be enforceable; and (b) make a good-faith effort to replace
any void, invalid, or unenforceable term or provision with a valid and enforceable term or provision such that the objectives contemplated by the parties hereto when entering this Agreement may be realized. 

 

	 	6.11	 Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between
the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

 

	 	6.12	 Specific Enforcement. The parties hereto agree that irreparable damage would occur in the event that
any of the provisions of this Agreement were not performed in accordance with their specific intent or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent or cure breaches
of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they may be entitled by law or equity. 

 

	 	6.13	 Exclusive Jurisdiction; Venue. Each of the parties hereto irrevocably agrees that any legal action or
proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by another party
hereto or its successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery, or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any federal court within the State of
Delaware, or, if both the Delaware Court of Chancery and the federal courts within the State of Delaware decline to accept jurisdiction over a particular matter, any other state court within the State of Delaware, and, in each case, any appellate
court therefrom. Each of the parties hereto hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and
agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by this Agreement in any court other than the aforesaid courts. Each of the parties hereto hereby irrevocably waives, and agrees not to
assert as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above named courts for any reason other than the failure to
serve in accordance with this Section 6.13, (b) any claim that it or its property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through service
of 

  
 22 

	 	 
notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted by the applicable Law, any claim
that (i) the suit, action or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or
by such courts. Each of the parties hereto agrees that service of process upon such party in any such action or proceeding shall be effective if such process is given as a notice in accordance with Section 6.5.

  

	 	6.14	 Publicity. Except as set forth below, no public release or announcement concerning the transactions
contemplated hereby shall be issued by the Investor without the prior consent of the Company, except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in
which case the Investor shall allow the Company reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, the Investor may identify the Company and the value of the Investor’s
security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies without prior notice to or consent from the Company (including, for the avoidance of doubt, filings pursuant to
Sections 13 and 16 of the 1934 Act). 

  

	 	6.15	 Survival. The representations, warranties, covenants and agreements contained in this Agreement shall
survive the Closing for a period of one year following the Closing Date. 

  

	 	6.16	 Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES TO THE EXTENT
PERMITTED BY APPLICABLE LAW ANY AND ALL RIGHT TO A TRIAL BY JURY IN ANY DIRECT OR INDIRECT ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY (A) CERTIFIES
THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) MAKES THIS WAIVER VOLUNTARILY,
AND (C) ACKNOWLEDGES THAT EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN THIS SECTION 6.16. 

[Remainder of page intentionally left blank] 

  
 23 

 IN WITNESS WHEREOF, the parties have executed this Stock Purchase Agreement
as of the date first written above. 
  

					
	 COMPANY:

	
	VACCINEX, INC.
		
	 By:
	 	 /s/ Maurice Zauderer

	 Name: Maurice Zauderer

	 Title: Chief Executive Officer

					
		
	 Address:
	 	 1895 Mount Hope Avenue

		 		 	 Rochester, New York 14620

	
	 With a copy to:

			
		 		 	 Hogan Lovells US LLP

		 		 	 100 International Drive

		 		 	 Suite 2000

		 		 	 Baltimore, Maryland 21202

		 		 	 Attn: William Intner

  

  
 [Signature Page to
Stock Purchase Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Stock Purchase Agreement
as of the date first written above. 
  

			
	 INVESTOR:

	
	FRIEDBERG GLOBAL-MACRO HEDGE FUND LTD.
		
	 By:
	 	 /s/ Albert Friedberg

	 Name: Albert Friedberg

	 Title: Director

 
			
		
	 Address:
	 	 190 Elgin Avenue

		 	 George Town

		 	 Cayman Islands KY1-9005

	
	 E-Mail Address: funds@friedberg.com

  
 [Signature Page to
Stock Purchase Agreement] 

 EXHIBIT A 

Registration Rights Agreement 

(Attached) 

 EXHIBIT B 

Investor Questionnaire 

(Attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]